Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment.

Shikuma CM, Wojna V, De Gruttola V, Siriwardhana C, Souza SA, Rodriguez-Benitez RJ, Turner EH, Kallianpur K, Bolzenius J, Chow D, Matos M, Shiramizu B, Clements DM, Premeaux TA, Ndhlovu LC, Paul R. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment. AIDS. 2023 11 01; 37(13):1987-1995.

View in: PubMed

subject areas

Antiretroviral Therapy, Highly Active
Cyclohexanes
HIV Infections
Humans
Triazoles

authors with profiles

Valerie Wojna
Bruce Shiramizu, MD
Kalpana Kallianpur, PhD
Cecilia M. Shikuma,MD
Dominic Chow, MD, PhD, MPH
Lishomwa Ndhlovu, MD PhD
Chathura Siriwardhana, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support